CONSTITUTIVELY ACTIVE PROLACTIN RECEPTOR VARIANTS AS PROGNOSTIC MARKERS AND THERAPEUTIC TARGETS TO PREVENT PROGRESSION OF HORMONE-DEPENDENT CANCERS TOWARDS HORMONE-INDEPENDENCE

摘要

The present invention relates to an in vitro method of prognosing outcome of hormone-dependent cancer in a subject comprising detecting a constitutively activating mutation in the prolactin receptor (PRLR) gene in a nucleic acid sample previously obtained from said subject, said constitutively activating mutation being preferably a mutation resulting in the expression of a mutant prolactin receptor wherein the isoleucine residue at position 146 is substituted with leucine or a mutation resulting in the expression of a mutant prolactin receptor wherein the isoleucine residue at position 76 is substituted with valine.